Myostatin (MSTN) and activin are members of the transforming growth factor-β superfamily. Both signal through the activin type II receptors (ActRII and ActRIIB). In a previous report, we demonstrated that fish possess at least 2 genes for ActRIIB: ActRIIB-1 and ActRIIB-2, which differ in their amino acid sequence. We also showed that affinity-purified, fish-soluble ActRIIB-1 (extracellular domain; ECD), produced in the yeast Pichia pastoris, inhibited recombinant mouse/rat/human mature MSTN activity in vitro using a reporter gene assay in the mammalian A204 cell line. In the present study, we produced soluble ActRIIB-2a in P. pastoris, and showed that it is N-glycosylated, similar to soluble ActRIIB-1. Inhibition of MSTN and activin A activities by affinity-purified ActRIIB-2a was compared with that of soluble ActRIIB-1 using the CAGA-luciferase assay in A204 cells. The findings of this study provide evidence that both paralogs, which probably resulted from gene duplication, did not diversify in their functionality (neofunctionalization), but rather retained a similar function. Both ActRIIB isoforms are equally potent in the mammalian system, and both exhibited an inhibitory effect on mammalian MSTN and activin A. Moreover--in spite of the amino acid differences in ECD between the two paralogs--it appears that the residues important for ligand binding are conserved, and that they recognize the mammalian ligands activin A and MSTN to the same extent.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1086/BBLv230n1p56 | DOI Listing |
Science
January 2025
Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Myostatin is a paracrine myokine that regulates muscle mass in a variety of species, including humans. In this work, we report a functional role for myostatin as an endocrine hormone that directly promotes pituitary follicle-stimulating hormone (FSH) synthesis and thereby ovarian function in mice. Previously, this FSH-stimulating role was attributed to other members of the transforming growth factor-β family, the activins.
View Article and Find Full Text PDFInt J Mol Sci
September 2024
Biohaven Pharmaceuticals Inc., New Haven, CT 06510, USA.
Spinal muscular atrophy (SMA) is a rare, genetic neurodegenerative disorder caused by insufficient production of survival motor neuron (SMN) protein. Diminished SMN protein levels lead to motor neuron loss, causing muscle atrophy and weakness that impairs daily functioning and reduces quality of life. SMN upregulators offer clinical improvements and increased survival in SMA patients, although significant unmet needs remain.
View Article and Find Full Text PDFJ Pharm Biomed Anal
January 2025
Doping Control Center, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; Divison of Bio-Medical Science & Technology, KIST School, Korea National University of Science and Technology, Seoul 02792, Republic of Korea. Electronic address:
Transforming growth factor-β superfamily members, such as myostatin, growth/differentiation factor 11, and activin A, negatively regulate skeletal muscle mass. Inhibitors targeting these cytokines or activin receptor type IIB have the potential to treat muscular diseases and enhance physical performance. However, because of their effects on muscle mass and potential misuse, they are strictly prohibited in sports.
View Article and Find Full Text PDFNutrients
August 2024
M2S (Laboratoire Mouvement, Sport, Santé)-EA 1274, Université Rennes, 35044 Rennes, France.
Objective: Obesity is associated with an exacerbated metabolic condition that is mediated through impairing balance in the secretion of some adipo-myokines. Therefore, the objective of the present study was to explore the impact of astaxanthin supplementation in conjunction with a 12-week CrossFit training regimen on some selected adipo-myokines, insulin insensitivity, and serum lipid levels in obese males.
Material And Methods: This study is a randomized control trial design; 60 obese males were randomly divided into four groups of 15, including the control group (CG), supplement group (SG), training group (TG), and combined training and supplement group (TSG).
J Cell Physiol
December 2024
Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, The Netherlands.
Simultaneous inhibition of transforming growth factor-β (TGF-β) type I receptors Acvr1b and Tgfbr1 signalling has been associated with excessive skeletal muscle hypertrophy in vivo. However, it remains unclear whether the increased muscle mass in vivo is a direct result of inhibition of intracellular TGF-β signalling or whether this is an indirect effect of an altered extracellular anabolic environment. Here, we tested whether individual or simultaneous knockdown of TGF-β type I receptors in C2C12 myotubes was sufficient to induce muscle hypertrophy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!